Physician profile
William Scott Dacus
NPI 1336162403
$8,894.62
in general payments reported to CMS, 2019-2025
61 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,875 · 2020: $367 · 2021: $122 · 2022: $1,015 · 2023: $2,067 · 2024: $1,747 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,395 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,395.03 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,079.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $726.05 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $649.50 | 2019-2025 | |
| Novo Nordisk INC | $620.10 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $601.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $451.78 | 2022-2025 | Freestyle Libre 3, Octrode |
| Glaxosmithkline, LLC. | $340.02 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $325.74 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $323.41 | 2019-2025 | Evenity, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $314.83 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.31 | 2019-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $248.93 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $219.64 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.68 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $213.18 | 2019-2025 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $195.30 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $153.74 | 2019-2023 | Trintellix |
| Amarin Pharma, INC. | $131.20 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.76 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Stryker Corporation | $118.37 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Biohaven Pharmaceutical Holding Company LTD. | $113.50 | 2022 | |
| Sumitomo Pharma America, INC. | $101.66 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $86.83 | 2025 | Rexulti |
| Corcept Therapeutics | $78.73 | 2024-2025 | Korlym |
| Daiichi Sankyo INC. | $73.85 | 2022-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $71.95 | 2024-2025 | Voquezna |
| Antares Pharma, INC. | $62.01 | 2019-2024 | Xyosted |
| Arbor Pharmaceuticals, INC. | $61.79 | 2019 | |
| Currax Pharmaceuticals LLC | $55.73 | 2023-2025 | Contrave, Nexletol |
| Esperion Therapeutics, INC. | $50.26 | 2023-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $50.14 | 2023-2025 | Rexulti |
| Tris Pharma INC | $48.55 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $47.61 | 2019 | Xyosted, Tlando |
| Inari Medical, INC. | $46.26 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Dynavax Technologies Corporation | $39.40 | 2024-2025 | Heplisav-B |
| Kowa Pharmaceuticals America, INC. | $35.79 | 2019 | |
| Neos Therapeutics, LP | $33.56 | 2023 | Adzenys Xr-Odt |
| Halozyme INC | $32.27 | 2023 | |
| Dexcom, INC. | $30.80 | 2024 | Dexcom G6 Transmitter |
| Optinose US, INC. | $30.48 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.45 | 2024-2025 | Caplyta |
| Hikma Pharmaceuticals USA | $28.88 | 2022-2024 | Ryaltris |
| Actelion Pharmaceuticals US, INC. | $27.90 | 2024 | Opsumit, Uptravi |
| Genentech USA, INC. | $27.31 | 2019 | |
| Ironwood Pharmaceuticals, INC | $27.24 | 2019 | |
| Axsome Therapeutics, INC. | $25.41 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $20.90 | 2023 | Strensiq |
| Edwards Lifesciences Corporation | $20.65 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $19.43 | 2025 | Ams 700 |
| Acadia Pharmaceuticals INC | $19.14 | 2025 | Nuplazid |
| Ironshore Pharmaceuticals INC. | $18.43 | 2019 | |
| Tolmar, INC. | $14.20 | 2023 | |
| Evofem Biosciences, INC. | $13.91 | 2022 | |
| Adlon Therapeutics L.P. | $13.79 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.38 | 2024 | Quviviq |
| Acerus Pharmaceuticals Corporation | $13.18 | 2021 | |
| Corium, LLC | $12.83 | 2022 | |
| Circassia INC. | $11.92 | 2019 | |
| Shire North American Group INC | $11.15 | 2019 | |
| Allergan, INC. | $11.06 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dacus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.